Rodolfo Fernando R.
- Country
- Italy
- Department
- Nefrologia e Dialisi
Research Overview
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
- Efficacy and Safety of Finerenone in Non-Diabetic Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
- Efficacy and Safety of Baxdrostat and Dapagliflozin on Renal and Cardiovascular Outcomes in Chronic Kidney Disease with Hypertension
Data & Insights
Has run more than one trial at 105 of 306 partner sites.
Specializations
Renal Medicine
The investigator specializes in treating patients with chronic kidney disease (CKD), focusing on innovative therapeutic approaches for managing progressive renal conditions.
- Renal Function Management
- Glomerular Filtration Assessment
- Progressive Kidney Disease
Their work encompasses comprehensive evaluation of renal function through estimated glomerular filtration rate (eGFR) monitoring.
Cardiovascular Health
The investigator demonstrates particular expertise in managing hypertension in patients with concurrent kidney conditions, exploring integrated treatment approaches.
- Blood Pressure Management
- Cardiovascular Risk in CKD
- Hypertension Treatment
Their focus includes developing strategies for blood pressure control in complex renal patients.
Combined Therapeutic Approaches
The investigator explores combination therapy strategies for patients with concurrent renal and cardiovascular conditions, examining novel therapeutic combinations.
- Multi-modal Treatment
- Therapeutic Innovation
- Disease Progression Management
Their expertise extends to evaluating therapeutic efficacy in complex medical conditions requiring multiple interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.